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Favourable pharmacokinetics of the prodrug are essential for successful HSVtk/ganciclovir (GCV) suicide gene therapy. [
18F]FHPG
PET might be a suitable technique to assess the pharmacokinetics of the prodrug GCV noninvasively, provided that [
18F]FHPG
mimics the behaviour of GCV. Since membrane transport is an important aspect of the pharmacokinetics of the prodrug, we
investigated the cellular uptake mechanism of [
18F]FHPG in an HSVtk expressing C6 rat glioma cell line and in tumour-bearing rats.
The nucleoside transport inhibitors dipyridamol, NBMPR and 2-chloroadenosine did not significantly affect the [
18F]FHPG uptake in
vitro. Thymidine and uridine significantly decreased [
18F]FHPG uptake by 84 and 58%, respectively, but an enzyme assay revealed that
this decline was due to inhibition of the HSVtk enzyme rather than membrane transport. Nucleobase transport inhibitors, thymine
and adenine, caused a 58 and 55% decline in tracer uptake, respectively. In vivo, the ratio of [
18F]FHPG uptake in C6tk and C6
tumours decreased from 3.070.5 to 1.070.2 after infusion of adenine. Thus, in our tumour model, [
18F]FHPG transport exclusively
occurred via purine nucleobase transport. In this respect, FHPG does not resemble GCV, which is predominantly taken up via the
nucleoside transporter, but rather acyclovir, which is also taken up via the purine nucleobase carrier.
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Suicide gene therapy offers a potential treatment modality for
various forms of cancer. Hitherto, the herpes simplex virus type 1
thymidine kinase gene (HSVtk) is the most frequently studied
suicide gene. Expression of the HSVtk gene renders tumour cells
sensitive to antiviral agents like ganciclovir (GCV). Compared to
human thymidine kinase, HSVtk is less substrate specific and
therefore can efficiently convert GCV to its monophosphate, which
is phosphorylated further to the corresponding di- and tripho-
sphate by host cellular kinases (Cheng et al, 1983). These
metabolites are toxic for the cells and consequently tumour cells
in which the HSVtk gene is expressed are killed (Culver et al, 1992;
Freeman et al, 1993). However, clinical results remain disappoint-
ing because the conditions for clinical gene therapy protocols are
not yet optimal. Low efficiency of gene transfer to the target cells
seems to be the major problem. Another important issue is the
safety profile of the therapy: in general, invasion of the gene
transduction vector in nontarget organs can induce serious
toxicity (Somia and Verma, 2000). To optimise HSVtk gene
therapy, an in vivo detection method for HSVtk activity would be
extremely helpful. Positron Emission Tomography (PET) imaging
with a suitable tracer can provide useful information about the
location and the extent of the HSVtk enzyme activity as a function
of time.
Several radiolabelled thymidine and GCV derivatives have been
studied as potential tracers for imaging of HSVtk enzyme activity
with PET. After phosphorylation, these compounds remain
trapped within cells and are therefore suitable for imaging. We
and others have shown that HSVtk gene expression can success-
fully be monitored with 9-[(3-[
18F]fluoro-1-hydroxy-2-propoxy)-
methyl]guanine ([
18F]FHPG) and PET (Alauddin et al, 1999;
Hospers et al, 2000). Recently, other radiolabelled nucleoside
analogues – especially 20-fluoro-20-deoxy-1-b-D-arabinofuranosyl-
5-iodouracil (FIAU) – have shown to be more sensitive probes for
HSVtk expression than [
18F]FHPG, as FIAU accumulation in
HSVtk transduced tumours was up to 119 times higher than that of
FHPG (Brust et al, 2001; Tjuvajev et al, 2002).
The observed difference in sensitivity between FIAU and FHPG
cannot be explained by differences in affinity for the HSVtk
enzyme alone. The affinities of several nucleoside analogues for
HSVtk have previously been determined in thymidine kinase
assays using purified HSVtk enzyme. Cheng et al (1981) showed
that the relative phosphorylation rates of the thymidine derivatives
20-fluoro-20-deoxy-1-b-D-arabinofuranosyl-5-methyluracil
(FMAU) and FIAU (expressed as percentage of the phosphoryla-
tion rate of thymidine) were 42 and 104%, respectively. In another
HSV-1 strain, Martin et al (1986) showed that phosphorylation
rates of the acyclic guanosine analogues GCV and FHPG were 98
and 67% relative to thymidine, respectively. These results indicate
that the affinities of GCV, FHPG, FMAU and FIAU for the HSVtk
enzyme are comparable and cannot explain the large difference Revised 3 June 2004; accepted 25 August 2004
*Correspondence: Drs AR Buursma; E-mail: a.r.buursma@pet.azg.nl
British Journal of Cancer (2004) 91, 2079–2085
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $30.00
www.bjcancer.com
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sbetween FIAU and FHPG accumulation in HSVtk transduced
tumours. Apparently, other factors than the affinity for the HSVtk
enzyme play an important role in tracer/prodrug uptake.
This hypothesis is in agreement with the results of Beck et al
(1995), who found that different tumour cells that expressed
similar levels of HSVtk could display highly different suscep-
tibilities to GCV in vitro. Similar results were obtained in vivo:
mammary adenocarcinomas (TSA-tk tumours) could be elimi-
nated in almost all animals by systemic GCV administration
(150mgkg
 1 GCV i.p. twice daily during 5 days), whereas T-cell
lymphomas (ESB-tk tumours) were completely resistant to GCV
treatment. Haberkorn et al (1998) suggested that membrane
transport might be a limiting factor for HSVtk/GCV suicide gene
therapy, as tritiated GCV enters the cell mainly via relatively slow
active membrane transport. Therefore, for successful HSVtk/GCV
suicide gene therapy, not only the level of suicide gene expression
but apparently also the rates of uptake and conversion of the
prodrug into the toxic substance, the prodrug pharmacokinetics,
are important. To discriminate between responders and non-
responders in an early stage of treatment, a method to
noninvasively measure the pharmacokinetics of the prodrug would
be helpful. The dynamics of various enzyme systems have been
studied with PET and a suitable radiolabelled compound. The best-
known example is probably [
18F]fluorodeoxyglucose, that is used
to study the glucose metabolism. In a similar manner, [
18F]FHPG
PET could be of benefit to study HSVtk prodrug pharmacokinetics.
In clinical studies on HSVtk suicide gene therapy, GCV has been
used as the prodrug. Thus far, a suitable method to label GCV with
a PET isotope (i.e.
11C) is not available. Owing to the structural
resemblance between FHPG and GCV (Figure 1), we hypothesised
that [
18F]FHPG PET could be applied to assess the pharmacoki-
netics of the prodrug (de Vries et al, 2003). However, the
replacement of the -OH group in the structure of GCV with -F
does not guarantee identical pharmacokinetic properties. There-
fore, the pharmacokinetic profile of FHPG remains to be
investigated.
It has already been shown that the phosphorylation character-
istics of HSVtk for the substrates GCV and FHPG are comparable
(Martin et al, 1986). However, pharmacokinetics are not only
determined by phosphorylation but also by transport of the drug
from plasma into the cell. At present, little is known about
transport of FHPG across the cell membrane. To investigate
whether the transport mechanism of FHPG resembles that of GCV,
this study aimed to elucidate the transport mechanism of FHPG.
MATERIALS AND METHODS
Materials
Dulbecco’s minimum essential medium (DMEM), geneticin
(G418), trypsin (2.5% (wv
 1)) and bovine serum albumin (BSA)
were purchased from Invitrogen (Merelbeke, Belgium). Foetal calf
serum (FCS) and Matrigel were obtained from PAA laboratories
(Brunschwig, Amsterdam, The Netherlands). Thymidine, uridine,
2-chloroadenosine, thymine, adenine, dipyridamole, nitroben-
zylthioinosine (NBMPR), dithiothreitol (DTT) and aprotinin were
obtained from Sigma-Aldrich (St Louis, MO, USA). GCV was
obtained from Roche (Mijdrecht, The Netherlands). Tris, potas-
sium chloride (KCl), potassium dihydrophosphate, dipotassium
hydrophosphate, magnesium chloride (MgCl2), glycerol, isopro-
panolol, phenylmethylsulphonyl fluoride (PMSF) and Titriplex
(EDTA) were purchased from Merck (Darmstadt, Germany).
Phosphate-buffered saline (PBS) and sodium fluoride (NaF) were
purchased from the Department of Pharmacy (Groningen Uni-
versity Hospital, Groningen, The Netherlands). Adenosine triphos-
phate (ATP) was obtained from Pharmacia BV (Woerden, The
Netherlands). Whatman ion-exchange DE-81 filter paper disks
were purchased from VWR International (Roden, The Nether-
lands).
Preparation of [
18F]FHPG
[
18F]FHPG was prepared as described by Alauddin et al (1996)
with minor modifications. The fluorination reaction was carried
out at 1251C for 30min and the subsequent hydrolysis was
performed at 901C for 5min. The reaction mixture was neutralised
by the addition of sodium phosphate buffer (pH 7.2) prior to
purification by high-performance liquid chromatography (HPLC),
which was performed over a semipreparative Alltima C18 reverse-
phase column (5mm, 10 250mm
2. Alltech, Deerfield, IL, USA)
using 3% EtOH, 10mM NaH2PO4 in saline as the eluent (flow:
5mlmin
 1, Rt: 16min). Radiochemical yield: 5–15% (corrected for
decay). Radiochemical purity 499% (HPLC: Nova Pak C18, 3mm,
9 150mm, 2% acetonitrile, 1mlmin
 1, Rt: 6min).
Cell lines
C6 rat glioma cells obtained from the American Type Culture
Collection were cultured in monolayers in DMEM supplemented
with 5% FCS in a humidified atmosphere with 5% CO2 at 371C.
HSVtk positive C6 cells (C6tk) were obtained by transfection of the
C6 cells with supernatant of PA-317tk packaging cells containing
replication incompetent retroviruses carrying the HSVtk gene and
the NeoR gene. Subsequent G418 selection resulted in the C6tk cell
line. Stable resistance in the C6tk cells was assured by culturing
this cell line in the presence of G418 (0.5mgml
 1). The packaging
cell PA-317tk was a gift from Dr SG Marcus (Genetic Therapy Inc.,
Gaithersburg, MD, USA).
Preparation of crude cell lysates
Approximately 1.5 10
7 cells were trypsinised and washed twice
with cold PBS, after which the cells were kept on ice and lysed in
0.5ml lysis buffer (20mM Tris buffer, pH 8.1, 40mM KCl, 1mM
EDTA, 1mM DTT, 1mM PMSF, 1mgml
 1 aprotinin and 10%
glycerol) (Hinds et al, 2000) by sonification (Soniprep 150, MSE,
Leicestershire, UK) for 4–6 times 15s. The homogenate was
centrifuged at 15000g for 20min to separate insoluble material.
Protein concentrations were determined according to Bradford
(1976) and lysates were diluted to a concentration of
5mgproteinml
 1 and stored at  801C.
Accumulation of [
18F]FHPG in tumour cells
C6 cells and C6tk cells were seeded in 12-well culture plates with
1.5ml of DMEM supplemented with 5% FCS. After 24h at 371C,
monolayers had grown. The medium was removed and replaced
with 1.5ml of DMEM supplemented with either the inhibitors of
the equilibrative facilitated diffusion nucleoside transport systems
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Figure 1 The chemical structures of GCV, FHPG and ACV.
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sdipyridamole and NBMPR (both to a final concentration of 5mM),
the substrates of the concentrative sodium-dependent nucleoside
transporters 2-chloroadenosine, thymidine and uridine, the
nucleobase transport inhibitors thymine and adenine, or with
GCV (all to a final concentration of 2mM). After 20min of
preincubation with these transport inhibitors at 371C,
2.471.1MBq of [
18F]FHPG was added to each well. After 20min
of tracer incubation, the culture medium was removed and the
monolayers were washed three times with 1ml PBS. The cells were
harvested from the culture plates by treatment with 0.25ml trypsin
for approximately 5min. When the cells were detached from the
bottom of the well, the cells were resuspended in 1.2ml of culture
medium to neutralise the trypsin. A 50ml sample was taken and
mixed with 50ml trypan blue to count the number of viable cells
under a microscope. The radioactivity in the cell suspensions was
measured in a gamma counter (LKB, Wallac, Turku, Finland) and
normalised to the number of viable cells. Results are reported as
the percentage [
18F]FHPG uptake relative to the [
18F]FHPG uptake
in C6tk cells that were not pretreated with a transport inhibitor.
For each transport inhibitor, at least three independent experi-
ments were performed. For GCV, two independent experiments
were performed in duplicate and triplicate, respectively. Statistical
analysis was performed on the raw data (n¼5–12), using the two-
sided unpaired student’s t-test. Po0.05 was considered significant.
Enzyme assay
The activity of the HSVtk enzyme in the crude cell lysates was
determined as described by Hinds et al (2000), using [
18F]FHPG as
a substrate. The following standard reaction mixture was used:
100ml of crude cell lysate, 20mM potassium phosphate (pH 7.6),
40mM KCl, 25mM NaF, 5mM MgCl2,1 m M DTT, 5mM ATP and
0.5mgml
 1 BSA in a total volume of 400ml. For inhibition
experiments, the reaction mixture was preincubated with 2mM 2-
chloroadenosine, thymidine, uridine, thymine, adenine or GCV for
5min at 371C. HSVtk activity was determined by incubating
0.17570.025MBq [
18F]FHPG in the reaction mixture at 371C for
20min. The reaction was stopped by loading two times 50mlo f
reaction mixture on two Whatman DE-81 filters. The negatively
charged phosphorylated [
18F]FHPG is bound to these filters. One
filter was washed three times for at least 2min with ammonium
formate and three times with 95% ethanol to remove unreacted
[
18F]FHPG. The unwashed filter (reflects both unchanged and
phosphorylated [
18F]FHPG) was used to normalise the activity
bound on the washed filter. Radioactivity of the filters was counted
with a gamma counter. [
18F]FHPG phosphorylation in the presence
of a transport inhibitor was calculated by dividing the radioactivity
(cpm) of the washed filters by the radioactivity of the unwashed
filters: (Aphos/Atot)inhib. Background correction was obtained from
control reactions that were performed in the reaction mixture
without the crude cell lysate: (Aphos/Atot)blanco. In each experiment,
[
18F]FHPG phosphorylation in the reaction mixture that was not
preincubated with an inhibitor (Aphos/Atot)cont was used as a
reference point. Results are reported as percentages inhibition of
[
18F]FHPG phosphorylation by the inhibitors according to the
formula:
inhibitionð%Þ¼ 1  
Aphos
Atot
  
inhib
 
Aphos
Atot
  
blanco
Aphos
Atot
  
cont
 
Aphos
Atot
  
blanco
0
B @
1
C A100%
For each inhibitor, three independent experiments were
performed in duplicate. Statistical analysis was performed on the
raw data (n¼6), using the two-sided unpaired student’s t-test.
Po0.05 was considered significant.
Animal model
To confirm the results of our in vitro experiments in an in vivo
model, the effect of blocking the purine nucleobase carrier with
adenine on the [
18F]FHPG uptake was investigated in tumour-
bearing rats. To this purpose, tumours were grown in female nude
rats (HSD Han RNU rnu; Harlan, the Netherlands; body weight,
140–200g) by injection of C6 or C6tk cells. Before injection, C6
and C6tk cells (2.5 10
6cells/0.1ml of DMEM/5% FCS) were
mixed with 0.1ml of Matrigel. Subsequently, the C6 and C6tk cell
suspensions were injected into the left and right flank, respectively,
close to the forelegs. At 9 or 10 days after injection of the tumour
cells, a solid tumour nodule of approximately 1.5cm in diameter
had grown in each flank. In this experimental setting, the animal
carried both an HSVtk containing tumour and a control tumour,
which minimises the effect of interindividual variation, because
each animal serves as its own control. All studies were carried out
in compliance with the national law and the local ethical guidelines
for animal experiments. The protocols were approved by the
Animal Ethics Committee of the Groningen University.
Accumulation of [
18F]FHPG in tumours
The tumour-bearing nude rats were anaesthetised by an intraper-
itoneal injection of sodium pentobarbital (60mgkg
 1 body
weight). During the experiment, the rats were kept warm by
heating pads. Rats in the adenine group (n¼3) were pretreated
with a 1ml bolus injection of a 33.875.4mM solution of adenine in
0.9% NaCl in the tail vein, 20min prior to tracer injection.
Immediately after the bolus injection, the rats were given a
constant infusion of the adenine solution (0.08mlmin
 1) via the
tail vein canula until the end of the experiment. Rats in the control
group (n¼3) were treated similarly with 0.9% NaCl only. For the
determination of the adenine serum concentration, in one rat,
blood samples were drawn from a carotis canula at different time
intervals (5, 15, 25, 40, 55 and 70min after the bolus adenine
injection). HPLC analysis, using the procedure described by Eells
and Spector (1983), revealed that a steady-state adenine serum
concentration of approximately 2mM was achieved. [
18F]FHPG
(37718 MBq in 0.2–0.6ml of HPLC eluent) was injected via the
tail vein canula of the rats by interrupting the adenine infusion for
a few seconds. After 1h of tracer distribution, the rats were killed
by extirpation of the heart. Tumours were dissected, weighed and
the accumulated radioactivity was measured with a gamma
counter. Tracer accumulation is expressed as the ratio between
the [
18F]FHPG accumulation per gram tissue in the C6tk tumour
and the C6 tumour. Statistical analysis was performed using the
two-sided unpaired student’s t-test. Po0.05 was considered
significant.
RESULTS
Accumulation of [
18F]FHPG in tumour cells
To elucidate the transport mechanism, uptake of [
18F]FHPG was
studied in the presence of known inhibitors of various nucleoside
and nucleobase transport systems. In the absence of inhibitors, the
accumulation of [
18F]FHPG was approximately 14 times higher in
C6tk cells than in HSVtk negative C6 cells (0.14070.043%ID/
10
6cells for C6Tk cells and 0.01170.004%ID/10
6cells for C6 cells)
after 20min of incubation with [
18F]FHPG. Dipyridamole and
NBMPR, inhibitors of the equilibrative facilitated diffusion
nucleoside transport systems, did not significantly affect the
[
18F]FHPG uptake. The substrates of the concentrative sodium-
dependent nucleoside transporters thymidine and uridine sig-
nificantly decreased tracer uptake by 8475 and 5875%,
respectively, whereas 2-chloroadenosine, which is also a substrate
of this nucleoside transporter, had no significant effect on the
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18F]FHPG uptake. After incubation with the nucleobase transport
inhibitors thymine and adenine, a significant decline in tracer
uptake of 5878 and 55717% was observed, respectively.
Incubation with GCV resulted in a decline in tracer uptake of
59714% (Figure 2).
Enzyme assay
To discriminate whether the reduction in [
18F]FHPG uptake was
due to inhibition of FHPG membrane transport or inhibition of the
HSVtk enzyme, an enzyme assay was performed. Thymidine,
uridine and GCV are substrates of HSVtk and competition with
FHPG could explain the decline in tracer uptake as well.
After preincubation of the crude cell lysate with a competitor, a
decline in [
18F]FHPG phosphorylation was seen of 2177% for 2-
chloroadenosine, 10173% for thymidine, 5177% for uridine,
50710% for thymine, 11710% for adenine and 9873% for GCV.
Figure 3 shows the inhibition of cellular uptake and phosphoryla-
tion of [
18F]FHPG by the inhibitors. A significant difference
between the decline in [
18F]FHPG phosphorylation in the enzyme
assay and [
18F]FHPG uptake in intact cells is seen after incubation
with thymidine, adenine or GCV. Adenine blocks a great part of
the [
18F]FHPG uptake in intact cells, but hardly affects phosphor-
ylation of [
18F]FHPG in the crude cell lysate. Thymidine and GCV,
on the other hand, almost completely inhibit [
18F]FHPG phos-
phorylation in the enzyme assay, but inhibit tracer uptake in intact
cells to a smaller extent.
Accumulation of [
18F]FHPG in tumours
To confirm the results of the in vitro experiments, the effect of
inhibition of the purine nucleobase carrier with adenine on the
[
18F]FHPG uptake was studied in tumour-bearing rats. At 1h after
tracer injection, tumours were excised and the [
18F]FHPG content
in the tumours was determined by ex vivo gamma counting.
In control rats, 3.070.5 times more [
18F]FHPG had accumulated
in the HSVtk expressing C6tk tumour than in the C6 control
tumour. After increasing the adenine plasma levels to approxi-
mately 2mM via adenine infusion, the difference in tracer uptake
between the positive and negative tumour was completely
abolished (ratio: 1.070.2). The decrease in tumour uptake ratio
as a result of adenine treatment was statistically significant
(Po0.005).
DISCUSSION
The aim of this study was to explore whether [
18F]FHPG PET could
be a suitable method to assess the pharmacokinetics of GCV. It has
already been shown that both FHPG and GCV are phosphorylated
by HSVtk to a similar extent (Martin et al, 1986). However, the
pharmacokinetics are not only determined by phosphorylation but
also by membrane transport. Whether FHPG also mimics GCV in
its transport across the cell membrane remained to be investigated.
In this study, we aimed to investigate whether FHPG and GCV are
carried across the cell membrane by the same transporter. To this
purpose, the accumulation of (
18F]FHPG in an HSVtk expressing
cell line and in HSVtk expressing tumours was examined.
Inhibition experiments were performed with different inhibitors
of nucleoside and nucleobase transport systems. In the literature,
two classes of nucleoside transporters have been described: the
equilibrative, nonconcentrative, facilitated diffusion systems and
the concentrative, Na
þ- and energy-dependent systems. In the
case of the equilibrative nucleoside transporters (ENT), the flux of
nucleoside molecules across the membrane is driven solely by the
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Figure 2 The relative [
18F]FHPG uptake in HSVtk expressing C6tk cells.
Cells were preincubated with 5mM dipyridamole, 5mM NBMPR, 2mM 2-
chloroadenosine, 2mM thymidine, 2mM uridine, 2mM thymine, 2mM
adenine, or with 2mM GCV for 20min at 371C. After the cells were
incubated with 2.471.1MBq of [
18F]FHPG for 20min, tracer uptake was
determined. The uptake of [
18F]FHPG in untreated C6tk cells was used as a
control. Results are reported as the percentage [
18F]FHPG uptake relative
to the [
18F]FHPG uptake in C6tk cells that were not pretreated with a
transport inhibitor. Error bars represent the standard deviation. Statistical
analysis was determined by the two-sided unpaired student’s t-test.
Significant differences between cells pretreated with an inhibitor and
control cells are indicated with symbols: *Po0.001; **Po0.005;
***Po0.05.
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Figure 3 The percentage of the inhibition of the phosphorylation and
cellular uptake of [
18F]FHPG after incubation with the inhibitors in both
intact cells and crude cell lysate, respectively. For the conditions of the
inhibition experiments with the intact cells, see legend to Figure 2. For
inhibition experiments with crude cell lysate, a standard reaction mixture
was preincubated with 2mM 2-chloroadenosine, thymidine, uridine,
thymine, adenine or GCV for 5min at 371C. HSVtk activity was determined
by incubating 0.17570.025MBq [
18F]FHPG in the reaction mixture at
371C for 20min. In each experiment, [
18F]FHPG phosphorylation in the
reaction mixture that was not preincubated with an inhibitor, was set at
100% (control value). Results are reported as percentages inhibition of
[
18F]FHPG phosphorylation by the inhibitors. Error bars represent the s.d.
Statistical analysis was determined by the two-sided unpaired student’s t-
test. Significant differences between inhibition of tracer uptake and
inhibition of phosphorylation are indicated with the symbol *(Po0.005).
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sconcentration gradient. Two subtypes have been described. The
equilibrative sensitive transporter (ENT1) is sensitive to low
nanomolar concentrations of NBMPR. The equilibrative insensi-
tive type (ENT2) is relatively insensitive to NBMPR. Both subtypes
are inhibited by nanomolar concentrations of dipyridamole
(Baldwin et al, 1999; Cass et al, 1999; Hyde et al, 2001). According
to the literature, C6 rat glioma cells express nucleoside transpor-
ters primarily of the ENT 2 subtype (Sinclair et al, 2000). In our C6
glioma cell line, we found no contribution of equilibrative,
facilitated nucleoside transport systems to the transport of FHPG.
Dipyridamole and NBMPR, both inhibitors of this transport
system, did not significantly affect [
18F]FHPG uptake.
The concentrative nucleoside transporters (CNT) can be
subdivided into three main types on the basis of their substrate
selectivities. The first type, cit, transports preferentially pyrimidine
nucleosides. The second type, cif, accepts purine nucleosides and
uridine. The third type, cib, accepts both purine and pyrimidine
nucleosides. All three types are typically insensitive to NBMPR
(Baldwin et al, 1999).
In our cell line, FHPG permeation was not significantly inhibited
by the purine nucleoside 2-chloroadenosine, which is also a
substrate of concentrative sodium-dependent nucleoside trans-
port. This indicates that transport of FHPG does not depend on the
cif or cib carrier. The pyrimidine nucleosides thymidine and
uridine, on the other hand, both decreased [
18F]FHPG uptake. This
could be evidence for transport of FHPG via the cit carrier.
Thymidine and uridine, however, are not only substrates of the cit
nucleoside transporter but also of the HSVtk enzyme. Competition
of these nucleosides with FHPG for the HSVtk enzyme might have
caused the observed effects. To discriminate between the reduction
in [
18F]FHPG uptake via inhibition of FHPG membrane transport
and inhibition of the HSVtk enzyme, an enzyme assay was
performed. In the enzyme assay, the decline in [
18F]FHPG
phosphorylation after preincubation with 2-chloroadenosine and
uridine corresponded well with the decline in tracer uptake as seen
in intact cells. This indicates that the decline in [
18F]FHPG uptake
as seen in the intact cells is caused by competition of these
compounds with [
18F]FHPG as substrates for the HSVtk enzyme
and not by inhibition of membrane transport. In the case of
thymidine, [
18F]FHPG phosphorylation is completely inhibited in
the enzyme assay, whereas the [
18F]FHPG uptake in the intact
cells is inhibited to a smaller extent. This probably means
that membrane transport of thymidine is the rate-limiting
step and as a consequence only low intracellular levels of
thymidine were achieved in our experiments. Therefore, the
decline in [
18F]FHPG uptake in intact cells is completely due to
competition of thymidine with [
18F]FHPG as a substrate for the
HSVtk enzyme. Additionally, the fact that the decline in tracer
uptake in intact cells is smaller than the reduction in FHPG
phosphorylation in the presence of thymidine, indicates that FHPG
is transported by another carrier than thymidine. Thus, in our cell
line, we found no evidence for concentrative nucleoside transport
for FHPG.
Nucleobase transport has been extensively studied. In certain
mammalian cells, separate carriers for hypoxanthine (guanine)
and adenine have been assumed to exist. In contrast, results of
other cell studies have suggested the existence of a single carrier
for purine nucleobase transport. In human erythrocytes purine
nucleobases share a common facilitated transport system, which is
functionally distinct from the nucleoside transporter (Domin et al,
1988).
To investigate the contribution of nucleobase systems to the
transport of FHPG, competition experiments with a pyrimidine
nucleobase (thymine) and a purine nucleobase (adenine) were
carried out. According to literature, the presence of at least two
nucleobase transporters is suggested in C6 rat glioma cells: NBT 1
and NBT 2 (Sinclair et al, 2000). Thymine and adenine caused a
significant decline in tracer uptake of 58 and 55%, respectively.
This suggests that FHPG is transported by purine and pyrimidine
nucleobase carriers.
However, the enzyme assays with crude cell lysate showed that
thymine inhibited [
18F]FHPG phosphorylation to a similar extent
as it inhibited cellular uptake of the tracer in intact cells. One of the
explanations for this observation could be a disturbed balance
between thymine metabolism and thymidine catabolism due to the
enormous excess of exogenous thymine. Normally, the following
reaction, catalysed by thymidine phosphorylase, maintains the
balance of the intracellular nucleotide pool:
Thymidine þ phosphateÐthymine
þ 2-deoxy-D-ribose-1-phosphate
Although the reaction is reversible, nucleic acid homeostasis
depends mainly on the catabolic reaction (Brown and Bicknell,
1998; Murray et al, 2002). The enormous increase in thymine levels
might reverse this balance. An increase in thymidine levels results
in an increased inhibition of [
18F]FHPG phosphorylation in the
crude cell lysate via competition for the HSVtk enzyme, and thus a
decreased uptake of the tracer in intact cells.
The fact that no clear difference was seen between the decline in
[
18F]FHPG phosphorylation in the crude cell lysate and the decline
in [
18F]FHPG uptake in intact cells indicates that there is no
inhibition of [
18F]FHPG membrane transport by thymine. There-
fore, no evidence for pyrimidine nucleobase transport for FHPG is
found in our cell line.
In the case of adenine, there was no inhibition on the [
18F]FHPG
phosphorylation in the enzyme assay. Together with the fact that a
clear difference was seen between the decline in [
18F]FHPG uptake
in crude cell lysate and in intact cells, this result indicates that the
reduction in [
18F]FHPG uptake as seen in intact cells was indeed
due to inhibition of the [
18F]FHPG transport. Also in vivo,a
complete block of the [
18F]FHPG uptake in HSVtk positive
tumours could be accomplished by infusion with the purine
nucleobase adenine. It follows from the above that FHPG enters
the C6 cells exclusively via the purine nucleobase carrier.
The goal of our experiments was to investigate if FHPG mimics
GCV in its transport across the cell membrane. Membrane
transport of GCV has been studied in different cell lines. In
human erythrocytes, GCV permeates the membrane both by the
purine nucleobase carrier and by the nucleoside transporter
(Mahony et al, 1991). In human mammary carcinoma (MCF7)
cells, nucleobase systems showed no significant contribution to
GCV uptake, as only transport via the nucleoside transport
systems was seen (Haberkorn et al, 1998). In rat Morris hepatoma
(MH3924A) cells, GCV was also transported by the nucleoside
transport systems (Haberkorn et al, 1997). So, in general, GCV is
primarily transported by the nucleoside transport systems. In our
experiments, we found only partial inhibition of [
18F]FHPG uptake
in intact cells by GCV, whereas GCV completely blocked
[
18F]FHPG phosphorylation in the enzyme assay. These results
are in agreement with the results of Haberkorn et al (1998), who
found that GCV enters the cell relatively slowly, mainly via the
nucleoside transport system. As a result of this slow GCV
transport, probably only low intracellular levels of GCV were
achieved in our experiments. Therefore, in intact cells, GCV only
partly inhibited [
18F]FHPG phosphorylation. FHPG membrane
transport was probably unaffected by GCV, because it utilises a
different transport system.
Thus, in our C6 tumour model, FHPG has proven to be
transported by the purine nucleobase carrier. The type transpor-
ters that are expressed in a cell can vary between tumour cells and
therefore in other tumour cell lines, other transporters may play a
role in the uptake of FHPG. However, our results show that
membrane transport of FHPG is different of that of GCV at least in
one cell line and we expect this to be the case also in other tumour
cell lines. Since GCV and FHPG in principle can be transported
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GCV membrane transport and therefore not suitable to monitor
GCV pharmacokinetics, irrespective of which transporters are
expressed in the tumour cell.
The fact that FHPG – in contrast to GCV – is primarily
transported by the purine nucleobase carrier might be explained by
the difference in the chemical structures of FHPG and GCV. It has
been shown for pyrimidine nucleoside probes that modification at
the 30-position, loss of a portion of the sugar ring, and lack of
conformational flexibility can decrease the affinity for the nucleo-
side transporters and can result in a decreased transport into the
cells (Gati et al, 1984). GCV has a relatively strong similarity to
nucleosides due to the presence of two hydroxymethyl groups on
its side chain and, therefore, can be transported by a nucleoside
transporter (Haberkorn et al, 1998). In the structure of FHPG, the
second hydroxyl group is missing (Figure 1) and as a result the
affinity for the nucleoside transporter could be lost.
The second hydroxyl group is also missing in the structure of
acyclovir (ACV), another acycloguanosine analogue, which is
phosphorylated by HSVtk. The HSVtk phosphorylation rate of
FHPG is intermediate between that of GCV and ACV (Martin et al,
1986). In human erythrocytes, ACV enters the cells mainly via the
purine nucleobase carrier (Mahony et al, 1988). Our results
indicate that in our C6 cell line model FHPG is also mainly
transported by the purine nucleobase carrier. Owing to this
resemblance in transport across the cell membrane and phosphor-
ylation characteristics, FHPG might be suitable to determine ACV
pharmacokinetics. This could be of clinical importance because the
GCV dose required for tumour regression is immunosuppressive,
whereas the required ACV dose is relatively nontoxic. Thus far,
ACV has not been used in a clinical HSVtk/ACV gene therapy
setting, because of the lower affinity for the HSVtk enzyme as
compared to GCV (Black et al, 2001). However, Black et al (2001)
recently developed HSVtk mutants with increased sensitivity
towards ACV. These mutants could bring HSVtk-mediated
activation of ACV to a clinically relevant level and, as a
consequence, HSVtk/ACV gene therapy could become of clinical
importance. Noninvasive imaging of ACV pharmacokinetics could
also play a role in other herpes related diseases, like for example,
Herpes Simplex Encephalitis (HSE), which is treated with high
doses of ACV. Case reports indicate that HSE may relapse after
ACV therapy. This relapse could, among others, be related to
persistence of infection (Skoldenberg, 1996). In addition, in
immunodeficient patients, ACV-resistant HSV isolates have been
identified (Roos, 1999). Additional studies are warranted to show
feasibility of [
18F]FHPG PET to assess the pharmacokinetics of
ACV at the onset of ACV treatment, which may allow prediction of
treatment outcome.
CONCLUSION
Our results show that the transport of FHPG in C6 cells exclusively
occurs by the purine nucleobase carrier. Thus, the transport
mechanism of FHPG appears to resemble that of ACV, rather than
GCV. As a consequence, FHPG cannot be used to measure GCV
pharmacokinetics. Whether [
18F]FHPG is suited to assess the
pharmacokinetics of the prodrug ACV or to predict the efficacy of
ACV treatment in HSVtk/ACV gene therapy or other herpes-
related diseases remains to be investigated.
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